| [1] |
Noris M,Caprioli J,Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype[J]. Clin J Am Soc Nephrol, 2010, 5(10): 1844-1859.
|
| [2] |
Besbas N,Karpman D,Landau D, et al. European Paediatric Research Group for HUS.A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders[J]. Kidney Int, 2006, 70(3): 423-431.
|
| [3] |
Taylor CM,Chua C,Howie AJ, et al. Clinicopathological findings in diarrhea-negative haemolytic uraemic syndrome[J]. Pedriatr Nephrol, 2004, 19(4): 419-425.
|
| [4] |
Rodríguez de Cordoba S. aHUS: a disorder with many risk factors[J]. Blood, 2010, 115(2): 158-160.
|
| [5] |
Heinen S,Hartmann A,Lauer N, et al. Factor H related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation[J]. Blood, 2009, 114(12): 2439-2447.
|
| [6] |
Jozsi M,Licht C,Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency[J]. Blood, 2008, 111(3): 1512-1514.
|
| [7] |
Noris M,Remuzzi G. Atypical hemolytic-uremic syndrome[J]. N Engl J Med, 2009, 361(17): 1676-1687.
|
| [8] |
Pechtl IC,Kavanagh D,Mcintosh N, et al. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities[J]. J Biol Chem, 2011, 286(13): 11082-11090.
|
| [9] |
Hocking HG,Herbert AP,Kavanagh D, et al. Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations[J]. J Biol Chem, 2008, 283(14): 9475-9487.
|
| [10] |
Licht C,Muus P,Legrende C, et al. Eculizumab is an effective long term treatment in patients with atypical hemolytic uremic syndrome previously receiving plasma exchange/plasma infusion (PE/PI): extension study results[J]. Blood, 2011, 118: abstr 3303.
|
| [11] |
Greenbaum L,Babu S,Furman RK, et al. Eculizumab is an effective, long term treatment in patients with atypical hemolytic uremic syndrome resistant to plasma exchange/ plasma infusion (PE/PI): results of an extension study[J]. Blood, 2011, 118: abstr 193.
|
| [12] |
Zipfel PF,Edey M,Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome[J]. PLoS Genet, 2007, 3(3): e41.
|
| [13] |
Fakhouri F,Roumenia L,Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations[J]. J Am Soc Nephrol, 2010, 21(5): 857-867.
|
| [14] |
Warwicker P,Goodship TH,Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome[J]. Kidney Int, 1998, 53(4): 836-844.
|
| [15] |
Manuelian T,Hellwage J,Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome[J]. J Clin Invest, 2003, 111(8): 1181-1190.
|